standard-title Studi Clinici

Studi Clinici

Titolo Fase Stato Sede patologia Strutture coinvolte Dettaglio

IZABRIGHT-BREAST01 - A RANDOMIZED, OPEN-LABEL, INFERENTIALLY SEAMLESS PHASE 2/3 STUDY OF IZALONTAMAB BRENGITECAN (BMS-986507) VERSUS TREATMENT OF PHYSICIAN’S CHOICE IN PATIENTS WITH PREVIOUSLY UNTREATED, LOCALLY ADVANCED, RECURRENT INOPERABLE, OR METASTATIC TRIPLENEGATIVE BREAST CANCER (TNBC) OR ER-LOW, HER2-NEGATIVE BC WHO ARE INELIGIBLE FOR ANTI- PD1/PD-L1 TREATMENT

II/III

in corso

CARCINOMA MAMMARIO

- SC Oncologia Clinica Sperimentale di Senologia

A MULTICENTRE, OPEN-LABEL, PHASE 3, RANDOMISED CONTROLLED TRIAL OF DUVELISIB VERSUS INVESTIGATOR’S CHOICE OF GEMCITABINE OR BENDAMUSTINE IN PATIENTS WITH RELAPSED/REFRACTORY NODAL T CELL LYMPHOMA WITH T FOLLICULAR HELPER (TFH) PHENOTYPE (TERZO)

III

in corso

linfoma

- SC Ematologia Oncologica

STUDIO IN APERTO PER LA PROSECUZIONE DELL’ACCESSO AL TRATTAMENTO DI PARTECIPANTI PROVENIENTI DAGLI STUDI SU ENCORAFENIB E BINIMETINIB C4221016 E C4221023 - (PROTOCOLLO MASTER ENCORAFENIB/BINIMETINIB: UNO STUDIO DI PROSECUZIONE IN APERTO PER I PARTECIPANTI PROVENIENTI DAGLI STUDI CLINICI CON ENCORAFENIB/BINIMETINIB)

II

in corso

MELANOMA

- SC Oncologia Clinica Sperimentale del Melanoma – Immunoterapia e Terapie Innovative

CIRCULATING EBV-DNA CHANGES IN TAILORING TREATMENT OF LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA: THE PHASE 2 TRIAL INTERLAYER

NA

in corso

CARCINOMA NASOFARINGEO

- SC Oncologia Clinica Sperimentale Testa – Collo

A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986504 MONOTHERAPY IN PARTICIPANTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH HOMOZYGOUS MTAP DELETION AFTER PROGRESSION ON PRIOR THERAPIES

II

in corso

CARCINOMA POLMONARE

- SC Oncologia Clinica Sperimentale Toraco - Polmonare